TrialThoracic cancer2023

Nivolumab as maintenance therapy following platinum-based chemotherapy in EGFR-mutant lung cancer patients after tyrosine kinase inhibitor failure: A single-arm, open-label, phase 2 trial.

Jiwon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.